Jianerkang Medical Co. Ltd. Class A

Jianerkang Medical Co. Ltd. Class A

SSSE:603205
20.63
CNY
-0.13
(-0.63%)
0.80EPS
27.32P/E
3.39BMarket Cap
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
7.86
15.6
6.68
9.34
8.82
8.44
6.53
7.08
Basic EPS, GAAP
0.72
3.69
1.12
1.34
1.05
0.97
0.71
0.8
Free Cash Flow per Basic Share
- -
3.55
0.19
0.83
0.63
0.82
0.57
- -
Dividend per Share
0.2
1.09
0.02
0.01
0.01
- -
0.27
- -
Book Value per Share
0.87
4.08
5.27
6.69
7.77
9.1
9.58
9.91
Tangible Book Value per Share
0.31
3.52
4.73
6.17
7.26
8.73
9.21
9.55
Basic Weighted Avg Shares
95
104
117
117
117
124
157
155
Sales/Revenue/Turnover
749
1,623
782
1,093
1,034
1,046
1,024
1,099
Operating Margin (%)
12.45
36.35
14.49
15.54
14.52
12.58
12.92
14.17
Depreciation Expense
- -
31
33
37
41
43
48
- -
Net Income, GAAP
69
384
132
157
124
120
111
123
Effective Tax Rate (%)
11.92
27.07
12.03
11.52
13.38
12.69
11.83
12.45
Profit Margin (%)
9.2
23.67
16.83
14.39
11.95
11.5
10.88
11.23
Working Capital
-216
114
235
369
475
1,000
1,042
1,036
LT Debt
- -
- -
- -
- -
- -
- -
17
13
Total Equity
101
477
617
783
909
1,420
1,494
1,546
Return on Invested Capital (%)
- -
92.41
56.45
127.58
31.14
13.19
8.73
8.37
Return on Capital (%)
- -
72.27
22.89
22.05
14.47
10.32
7.66
8.27
Return on Common Equity (%)
- -
132.9
24.07
22.47
14.6
10.32
7.65
8.3

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
4
4
5
LT Borrowings
- -
- -
- -
LT Finance Leases
15
14
13
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
156
156
156
Market Capitalization
4,005
3,192
3,391

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,197
1,231
1,237
Cash, Cash Equivalents & STI
772
799
777
Accounts Receivable, Net
204
199
218
Inventories
182
202
210
Total Current Liabilities
131
217
201
Payables & Accruals
- -
- -
- -
ST Debt
4
4
5
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
26.76%
5.23%
Free Cash Flow
- -
49.54%
-12.38%
Net Income, GAAP
- -
-15.54%
-7.31%
Sales/Revenue/Turnover
- -
-3.67%
-2.04%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
212
293
278
263
1,046
2025
241
225
- -
299
1,024
2026
238
255
307
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.22
0.31
0.21
0.17
0.97
2025
0.18
0.12
- -
0.22
0.71
2026
0.18
0.15
0.24
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
0.27
2026
- -
- -
- -
- -
- -

Company Description

CEO
Guo Ping Chen
Full Time Employees
1,694
Sector
Commercial services
Industry
Miscellaneous commercial services
Address
Changzhou China
IPO Date
Nov 7, 2024
Business
Jianerkang Medical Co., Ltd. is a China-based medical technology company primarily engaged in the research, development, manufacturing, and distribution of disposable medical consumables, advanced medical dressings, and disinfection and hygiene products. The company operates across six primary business segments: Surgical Consumables, including connecting tubes, high-negative-pressure drainage systems, suture needle counter boxes, surgical hand-scrub brushes, laryngeal mask airways, and single-use gastric tubes; Wound Care Products, comprising sterile post-operative dressings, transparent adhesive dressings, hydrocolloid dressings, alginate dressings, chitosan wound dressings, and activated carbon fiber dressings; Cleaning and Disinfection Products, featuring medical alcohol wipes and swabs, povidone-iodine prep pads and swabs, chlorhexidine and benzalkonium chloride solutions, hypochlorous acid disinfectants, hydrogen peroxide solutions, and hand sanitizing gels; Infection Control and Protection Supplies, including surgical face masks, medical protective masks, surgical gowns, and isolation garments; Polymer and Auxiliary Medical Devices, encompassing medical ultrasonic coupling gels, disposable oxygen humidification bottles, silicone urinary catheters, and ear irrigation syringes; and Non-Woven Fabrics and Consumer Hygiene Products, which include baby wipes, surface cleaning wipes, medical non-woven roll goods, cosmetic cotton pads, and dry disposable washcloths. Founded in 1999 and headquartered in Changzhou, Jiangsu Province, China, Jianerkang Medical serves healthcare facilities, retail pharmacies, and global medical brand owners. The company distributes its products across domestic medical networks and retail pharmacy chains in China while maintaining extensive international export operations across North America, Europe, Latin America, Asia, Africa, and Oceania through strategic supplier partnerships with global healthcare distributors, including Cardinal Health, Medline Industries, McKesson, and Owens & Minor. In recent developments, Jianerkang Medical completed its initial public offering on the Main Board of the Shanghai Stock Exchange in November 2024 under the ticker 603205, raising approximately RMB 386 million in net proceeds to finance the construction of production facilities for high-end functional medical dressings and non-woven materials, an upgraded research and development center, and integrated enterprise information technology infrastructure. Additionally, the company has undertaken strategic international manufacturing expansion by developing production facilities in Vietnam to optimize its global supply chain, mitigate cross-border trade risks, and accelerate market penetration for high-value medical polymers and advanced wound care solutions.